Skip to content

US · FTH · BIOTECHNOLOGY

Faeth Therapeutics, Inc. (FTH) intrinsic value and stock valuation

$7.88as of 2026-11-21 · Mkt cap 33M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Faeth Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values FTH with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from FTH’s statements →

Faeth Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Rockville, MD 20850 faeththerapeutics.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-21.09M
20182025
Free cash flow
-$-20.47M
20182025
Total equity
$18.6M+3.2% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-22.29M-$-31.66M-$-37.06M-$-49.12M-$-37.48M
Net income-$-21.09M-$-30.16M-$-34.1M-$-48.59M-$-36.79M
EPSd-$-16.74M-$-23.94M-$-24.36M-$-31.55M-$-26.47M
Operating cash flow-$-20.45M-$-24.67M-$-32.02M-$-39.03M-$-30.26M
Capital expenditure-$-20K-$-150K-$-180K-$-320K-$-2.03M
Free cash flow-$-20.47M-$-24.82M-$-32.2M-$-39.35M-$-32.28M
Total assets$22.9M$45.4M$74.4M$118.4M$153.2M
Total debt$1.51M$3.85M$6.21M$8.03M$2.35M
Net debt-$-7.16M-$-6.15M-$-6.8M-$-9.76M-$-4.8M
Total equity$18.6M$38.4M$64.9M$103.4M$146.5M
Cash and short-term investments$21.2M$41.3M$65.8M$107.1M$147.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$550K$570K$1.81M$690K
Gross profit$0.00-$-550K-$-570K-$-1.81M-$-690K
Research and development expenses$11M$18.6M$18.3M$29.6M$21.7M
Selling, general and administrative expenses$11.3M$12.5M$18.8M$17.7M$15.1M
Other expenses$0.00$0.00-$-570K$0.00$0.00
Operating expenses$22.3M$31.1M$36.5M$47.3M$36.8M
Cost and expenses$22.3M$31.7M$37.1M$49.1M$37.5M
Interest income$1.24M$2.55M$3.62M$1.78M$800K
Interest expense$30K$90K$140K$220K$670K
Depreciation and amortization$140K$550K$3.68M$1.81M$690K
Ebitda-$-20.91M-$-29.52M-$-33.39M-$-46.56M-$-35.44M
Operating income-$-22.29M-$-31.66M-$-37.06M-$-49.12M-$-37.48M
Total other income/expenses, net$1.2M$1.51M$2.96M$530K$690K
Income before tax-$-21.09M-$-30.16M-$-34.1M-$-48.59M-$-36.79M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-21.09M-$-30.16M-$-34.1M-$-48.59M-$-36.79M
Weighted average shares outstanding$1.26M$1.26M$1.4M$1.54M$1.39M
Weighted average diluted shares outstanding$1.26M$1.26M$1.4M$1.54M$1.39M
Balance sheet
20252024202320222021
Cash and short-term investments$21.2M$41.3M$65.8M$107.1M$147.6M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$21.5M$41.9M$67.3M$108.6M$148.5M
Property, plant and equipment, net$1.38M$3.38M$7.04M$9.72M$4.64M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.4M$3.43M$7.12M$9.79M$4.68M
Total assets$22.9M$45.4M$74.4M$118.4M$153.2M
Accounts payable$690K$240K$1.69M$4.47M$2.46M
Short-term debt$1.45M$2.32M$2.44M$2.13M$680K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.25M$5.45M$5.64M$9.07M$4.89M
Long-term debt$60K$1.53M$3.77M$5.9M$1.67M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$60K$1.53M$3.84M$5.9M$1.82M
Capital lease obligations$1.45M$3.85M$6.21M$8.03M$2.35M
Total liabilities$4.31M$6.97M$9.48M$15M$6.71M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-283.14M-$-262.05M-$-231.9M-$-197.79M-$-149.21M
Accumulated other comprehensive income (loss)$0.00-$-10K-$-210K-$-1M-$-330K
Total equity$18.6M$38.4M$64.9M$103.4M$146.5M
Total investments$12.5M$31.3M$52.8M$89.3M$140.5M
Total debt$1.51M$3.85M$6.21M$8.03M$2.35M
Net debt-$-7.16M-$-6.15M-$-6.8M-$-9.76M-$-4.8M
Cash flow statement
20252024202320222021
Net income-$-21.09M-$-30.16M-$-34.1M-$-48.59M-$-36.79M
Depreciation and amortization$140K$1.32M$1.35M$1.35M$690K
Stock-based compensation$1.27M$3.13M$4.45M$5.81M$5.66M
Change in working capital-$-1.59M-$-490K-$-4.33M$1.01M$120K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$230K-$-450K-$-2.33M$2.02M-$-1.43M
Net cash provided by operating activities-$-20.45M-$-24.67M-$-32.02M-$-39.03M-$-30.26M
Investments in property, plant and equipment-$-20K-$-150K-$-180K-$-320K-$-2.03M
Acquisitions, net$250K$0.00$170K$10K$320K
Net cash used for investing activities$19.8M$22.4M$38.4M$50M-$-143.12M
Common stock issued$10K$30K$50K$340K$140.6M
Common stock repurchased-$0.00$0.00-$-10.38M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-650K-$-790K-$-11.17M-$-290K$163.9M
Net change in cash-$-1.33M-$-3.02M-$-4.78M$10.6M-$-9.44M
Cash at end of period$8.67M$9.99M$13M$17.8M$7.16M
Operating cash flow-$-20.45M-$-24.67M-$-32.02M-$-39.03M-$-30.26M
Capital expenditure-$-20K-$-150K-$-180K-$-320K-$-2.03M
Free cash flow-$-20.47M-$-24.82M-$-32.2M-$-39.35M-$-32.28M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Faeth Therapeutics, Inc.

        Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

        CEO
        Anand Parikh
        Employees
        29
        Beta
        -0.31

        Explore

        Frequently asked questions

        What is the intrinsic value of Faeth Therapeutics, Inc. (FTH)?

        InvestorsCraft does not currently publish an intrinsic value for FTH. How the IC value is calculated.

        Is FTH undervalued?

        InvestorsCraft does not publish an undervaluation signal for FTH at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.